晚期胃癌患者PD-1阻断治疗期间的超进展疾病
本研究纳入169例晚期胃癌患者,其中112例接受PD-1抑制剂(纳武利尤单抗或帕博利珠单抗)单药治疗,57例接受伊立替康单药治疗作为对照。基于伊立替康组分析确定HPD最佳标准为肿瘤生长动力学比值和TGR比值均增加4倍且TGR增加40%。PD-1抑制剂组HPD发生率为10.7%(12/112),HPD患者无进展生存期和总生存期均缩短,且基线低白蛋白血症(<3.25 mg/dL)与HPD发生显著相关(P<0.001)。
要点
- PD-1抑制剂治疗的晚期胃癌患者中HPD发生率为10.7%(12/112)。
- HPD患者无进展生存期(HR 2.318)和总生存期(HR 2.542)均差于无HPD的进展患者。
- 基线低白蛋白血症(<3.25 mg/dL)与HPD发生显著相关(P<0.001)。
核心结论
- 部分接受PD-1抑制剂治疗的晚期胃癌患者会发生HPD,HPD与更差结局、丧失后续治疗资格及低白蛋白血症相关,需进一步研究。
研究设计与样本
- 研究纳入169例晚期胃癌患者,其中112例接受PD-1阻断(纳武利尤单抗或帕博利珠单抗)单药治疗,57例接受伊立替康单药治疗作为对照。
- 基于肿瘤生长动力学和肿瘤生长速率(TGR)分析肿瘤生长动态,并分析至治疗失败时间以定义HPD,探讨HPD的发生率、临床后果及预测标志物。
主要发现
- 基于伊立替康治疗患者的分析,HPD最佳标准为肿瘤生长动力学比值和TGR比值均增加4倍且TGR增加40%。
- PD-1抑制剂治疗患者中10.7%(12/112)发生HPD。
- HPD患者较无HPD的进展患者无进展生存期更短(HR 2.318;95%CI 1.205-4.460)且总生存期更短(HR 2.542;95%CI 1.314-4.918),并丧失后续系统治疗机会。
- 包括PD-L1表达在内的其他变量与HPD发生无关,但基线低白蛋白血症(<3.25 mg/dL)与HPD发生显著相关(P<0.001)且与更差生存结局相关。
关键数值与推荐
- HPD最佳标准:肿瘤生长动力学比值和TGR比值均增加4倍且TGR增加40%(基于伊立替康治疗患者分析)。
- HPD发生率:PD-1抑制剂组10.7%(12/112)。
- HPD患者无进展生存期HR 2.318(95%CI 1.205-4.460),总生存期HR 2.542(95%CI 1.314-4.918),均较无HPD的进展患者更差。
- 基线低白蛋白血症(<3.25 mg/dL)与HPD发生显著相关(P<0.001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文结论指出需进一步研究(warranting further investigation)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Investigations for programmed cell death-1 (PD-1) blockade-induced hyperprogressive disease (HPD) have not been stringently conducted in patients with advanced gastric cancer (AGC). We explored the occurrence of HPD and its clinical implications in patients with AGC and treated with PD-1 inhibitors. METHODS: We enrolled 169 patients with AGC and treated with either the PD-1 blockade (nivolumab or pembrolizumab; N = 112) or irinotecan monotherapy (N = 57) as a single agent. Tumour growth dynamics based on tumour growth kinetics and tumour growth rate (TGR) and time to treatment failure were analysed to define HPD. The incidence, clinical consequences and predictive markers of HPD were investigated. RESULTS: The optimal criteria for HPD were 4-fold increases in both tumour growth kinetics and TGR ratios and a 40% increase in TGR based on the analysis for patients treated with irinotecan. In total, 10.7% (12/112) of patients experienced HPD after PD-1 inhibitor treatment. Patients with HPD had both shorter progression-free survival (hazard ratio: 2.318; 95% confidence interval: 1.205-4.460) and overall survival (hazard ratio: 2.542; 95% confidence interval: 1.314-4.918) than patients with progressive disease without HPD, losing opportunities for subsequent systemic treatments. Although other variables including PD-L1 expression were not associated with the occurrence of HPD, hypoalbuminemia (<3.25 mg/dL) at baseline was significantly associated with the occurrence of HPD (P < 0.001) and inferior survival outcomes. CONCLUSIONS: HPD occurs in a proportion of patients with AGC and treated with PD-1 inhibitors. PD-1 inhibitor-induced HPD is associated with worse outcome, loss of eligibility for subsequent treatment and hypoalbuminemia, warranting further investigation.
引用
- Kim CG, Hong M, Jeung HC, et al. Hyperprogressive disease during PD-1 blockade in patients with advanced gastric cancer. Eur J Cancer. 2022. PMID: 35839733. doi:10.1016/j.ejca.2022.05.042
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。